Download the Visual
Sleep apnea, PCOS and diabetic retinopathy draw a fraction of GLP-1 development
Sleep apnea, PCOS and diabetic retinopathy together affect more than 1.1 billion people, yet each draws only a sliver of GLP-1 development. In Sleuth’s January 2026 analysis of 441 GLP-1 pathway assets, general obesity has close to 400 clinical-stage and approved programs, while obstructive sleep apnea (OSA) and polycystic ovary syndrome (PCOS) have roughly 20 each, 17 to 20 times less activity. The most valuable metabolic franchises may not come from out-competing Eli Lilly and Novo Nordisk in obesity, but from redeploying GLP-1 science where the label creates a reimbursement advantage.
Obstructive sleep apnea is a reimbursement play
OSA affects an estimated 936 million people worldwide, and about half of patients abandon CPAP devices. Sleuth’s reading is that the opportunity is less about new patients than about access. About 70% of OSA patients have obesity and are already reachable by obesity programs, but an OSA label with documented CPAP failure can establish medical necessity where obesity coverage meets payer resistance and formulary barriers.
The FDA approved Lilly’s tirzepatide (Zepbound) for moderate-to-severe OSA in adults with obesity in December 2024, the first drug approved for the condition, and because OSA is not a weight-loss indication, Medicare Part D plans can cover it. After this analysis, Medicare’s obesity gap narrowed: from July 2026, its temporary GLP-1 Bridge began covering Wegovy, Zepbound and Foundayo for eligible patients with obesity at a $50 copay per prescription through 2027.
An OSA label still gives a coverage path that does not depend on obesity policy, which in Medicare remains a time-limited demonstration. That is the kind of payer logic Sleuth covers in how indication selection dictates commercial strategy.
PCOS has no approved drug, and diabetic retinopathy is the least settled
PCOS affects more than 100 million women worldwide, and as of early 2026 no drug was FDA-approved specifically for it. Care relies on off-label drugs such as metformin, and small studies suggest GLP-1 agonists improve insulin resistance and ovulation. The chart places PCOS at the low end of competitive intensity, alongside OSA.
Diabetic retinopathy affects about 103 million people and is a leading cause of blindness in working-age adults, and it sits in the same low-competition zone of the chart. The GLP-1 evidence is mixed: semaglutide’s SUSTAIN-6 cardiovascular trial recorded more retinopathy complications than placebo, concentrated in patients with existing retinopathy and rapid glucose lowering.
OSA has the clearest case, with an approved GLP-1 and a coverage path. PCOS pairs a large population with little competition and no approved drug, while diabetic retinopathy needs outcome data before its white space becomes an opportunity. Sleuth’s GLP-1 Intelligence Report, Q3 2026 tracks how the incumbents are turning outcome trials into comorbidity labels.
Program counts come from Sleuth’s analysis of 441 GLP-1 pathway assets, published in January 2026; the visual is undated, and per-indication counts are approximate readings from the chart. Regulatory and coverage developments are current as of September 2026.
Frequently asked questions about GLP-1 white space
Which GLP-1 indications have the least competition?
In Sleuth’s January 2026 analysis of 441 GLP-1 pathway assets, obstructive sleep apnea, PCOS and diabetic retinopathy combine high disease burden with low competition. OSA and PCOS face 17 to 20 times less GLP-1 development activity than general obesity.
Is any drug approved for obstructive sleep apnea?
Yes. The FDA approved tirzepatide (Zepbound) for moderate-to-severe OSA in adults with obesity in December 2024, the first drug approved for OSA.
Are GLP-1 drugs approved for PCOS?
No. As of early 2026, no drug was FDA-approved specifically for PCOS, which affects more than 100 million women worldwide. GLP-1 agonists are used off-label, and small studies suggest they improve insulin resistance and ovulation.
Why would an OSA label help GLP-1 reimbursement?
In Sleuth’s view, an OSA indication with documented CPAP failure establishes medical necessity where obesity coverage faces payer resistance. Because OSA is not a weight-loss indication, Medicare Part D plans can cover tirzepatide for it, while Medicare’s obesity coverage runs through a temporary bridge from July 2026 through 2027.
